Fitch Ratings has changed its rating outlook on Natick-based Boston Scientific Corp. from negative to stable.
According to the company, the rating change is based on the progress it is making toward stabilizing its drug-eluting stent and cardiac rhythm management businesses and paying down its debt. Boston Scientific said it has paid down $1.7 billion in the past year.
Fitch’s long-term credit rating for the company remains a BB+.
